- Home
- RIGL vs HKD Comparison
RIGL vs HKD Comparison
Compare RIGL & HKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RIGL | HKD |
|---|---|---|
| Founded | 1996 | 2003 |
| Country | United States | France |
| Employees | N/A | 196 |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 537.6M | 487.1M |
| IPO Year | 2000 | 2022 |
Fundamental Metrics
Financial Performance| Metric | RIGL | HKD |
|---|---|---|
| Price | $49.33 | $1.52 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $43.20 | N/A |
| AVG Volume (30 Days) | 638.4K | ★ 760.3K |
| Earning Date | 11-04-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2698.26 | N/A |
| EPS | ★ 6.20 | N/A |
| Revenue | ★ $282,076,000.00 | $87,436,000.00 |
| Revenue This Year | $65.53 | N/A |
| Revenue Next Year | $0.22 | N/A |
| P/E Ratio | ★ $7.89 | $13.40 |
| Revenue Growth | ★ 79.13 | N/A |
| 52 Week Low | $14.63 | $1.36 |
| 52 Week High | $52.24 | $5.47 |
Technical Indicators
Market Signals| Indicator | RIGL | HKD |
|---|---|---|
| Relative Strength Index (RSI) | 64.29 | 44.93 |
| Support Level | $43.81 | $1.47 |
| Resistance Level | $52.24 | $1.62 |
| Average True Range (ATR) | 3.35 | 0.10 |
| MACD | -0.13 | 0.01 |
| Stochastic Oscillator | 75.13 | 55.16 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About HKD AMTD Digital Inc. (every five of which represent two)
AMTD Digital Inc along with its subsidiaries, is mainly involved in the provision of digital solutions services. Its reportable segments are digital solutions services segment, hotel operations, hospitality and VIP services segment and media and entertainment services. The company generates maximum revenue by providing financial digital solutions through its insurance brokerage services and other digital solutions services. Geographically, the company generates maximum revenue from Hong Kong and Singapore.